DAXANLO 150mg capsules medication leaflet

B01AE07 dabigatran etexilat • Blood and blood forming organs | Antithrombotic agents | Direct thrombin inhibitors

Dabigatran etexilate is an oral anticoagulant used for the prevention and treatment of blood clots. It is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).

Dabigatran etexilate works as a direct thrombin inhibitor, preventing the formation of blood clots. It is administered orally in capsule form, with the dosage adjusted based on the patient's condition and bleeding risk.

Side effects may include bleeding (nasal, gastrointestinal, or other types), dyspepsia (heartburn), nausea, or allergic reactions. It is contraindicated in patients with active bleeding, severe renal impairment, or hypersensitivity to the substance. It should also be used cautiously in patients with a high risk of bleeding.

General data about DAXANLO 150mg

Substance: dabigatran etexilat

Date of last drug list: 01-05-2026

Commercial code: W69917003

Concentration: 150mg

Pharmaceutical form: capsules

Quantity: 60

Product type: generic

Price: 150.43 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: KRKA, D.D., NOVO MESTO - SLOVENIA

Holder: KRKA, D.D., NOVO MESTO - SLOVENIA

Number: 15252/2023/03

Shelf life: 2 years

Pharmaceutical forms available for dabigatran etexilat

Concentrations available for dabigatran etexilat

110mg, 150mg, 20mg, 30mg, 40mg, 50mg, 6.25mg/ml, 75mg

Other substances similar to dabigatran etexilat

Compensation lists for DAXANLO 150mg KRKA

B - Sublist B with 50% discount from the reference price

Price

Copayment

Patient

150.43 RON

75.21 RON

75.22 RON